A composition comprising a Gα s protein coupled receptor agonist, or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing a fibrotic pathology, the method comprising administering to a subject in need thereof a therapeutically effective amount of said composition, wherein Gα s protein coupled receptor is preferentially expressed in mesenchymal cells as compared to epithelial or endothelial cells, and the agonist is specific for Gα s receptor that is expressed preferentially in the mesenchymal cell, wherein the Gα s protein coupled receptor is a dopamine receptor, and wherein the agonist agonizes both D1 and D5 dopamine receptors, wherein the agonist is selected from dihydrexidine (DHX), SKF-81297, SKF-82958, SKF-38393, fenoldopam, 6-Br-APB, A-68930, A-77636, CY-208-243, pergolide, R(-)-2,10,11-trihydroxyaporphine, (R)-(-)-apomorphine, R(-)-propylnorapomorphine, R(+)-6-bromo-APB, R(-)-2,10,11-trihydroxy-N-propyl-noraporphine, 6,7-ADTN, mesulergine, N-methyldopamine, 4-hydroxyphenethylamine, 3-hydroxyphenethylamine, pramipexole, PD-168077, (±)-PD 128-907, (±)-2-(N-phenylethyl-N-propyl)amino-5-hydroxytetralin, bromocriptine, ropinirole, LY-163-502, dipropyldopamine, B-HT 920, piribedil, (+)-UH 232, (-)-quinpirole, R(-)-2,11-dihydroxy-10-methoxyapomorphine, or a pharmaceutically acceptable salt thereof, or wherein the agonist is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of R 1 , R 2 , R 3 , R 4 and R 5 is independently selected from H, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, HO-C 1-3 alkyl, NH 2 -C 1-3 alkyl, HS-C 1-3 alkyl, SH, NH 2 , C 1-6 alkylamino and di(C 1-6 alkyl)amino, optionally wherein at least one of R 1 , R 2 , R 3 , R 4 and R 5 is selected from OH, C 1-6 alkoxy, C 1-6 haloalkoxy, HO-C 1-3 alkyl, NH 2 -C 1-3 alkyl, HS-C 1-3 alkyl, SH, NH 2 , C 1-6 alkylamino and di(C 1-6 alkyl)amino. wherein Gα s protein coupled receptor is preferentially expressed in mesenchymal cells as compared to epithelial or endothelial cells, and the agonist is specific for Gα s receptor that is expressed preferentially in the mesenchymal cell, wherein the Gα s protein coupled receptor is a dopamine receptor, and wherein the agonist agonizes both D1 and D5 dopamine receptors, wherein the agonist is selected from dihydrexidine (DHX), SKF-81297, SKF-82958, SKF-38393, fenoldopam, 6-Br-APB, A-68930, A-77636, CY-208-243, pergolide, R(-)-2,10,11-trihydroxyaporphine, (R)-(-)-apomorphine, R(-)-propylnorapomorphine, R(+)-6-bromo-APB, R(-)-2,10,11-trihydroxy-N-propyl-noraporphine, 6,7-ADTN, mesulergine, N-methyldopamine, 4-hydroxyphenethylamine, 3-hydroxyphenethylamine, pramipexole, PD-168077, (±)-PD 128-907, (±)-2-(N-phenylethyl-N-propyl)amino-5-hydroxytetralin, bromocriptine, ropinirole, LY-163-502, dipropyldopamine, B-HT 920, piribedil, (+)-UH 232, (-)-quinpirole, R(-)-2,11-dihydroxy-10-methoxyapomorphine, or a pharmaceutically acceptable salt thereof, or wherein the agonist is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of R 1 , R 2 , R 3 , R 4 and R 5 is independently selected from H, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, HO-C 1-3 alkyl, NH 2 -C 1-3 alkyl, HS-C 1-3 alkyl, SH, NH 2 , C 1-6 alkylamino and di(C 1-6 alkyl)amino, optionally wherein at least one of R 1 , R 2 , R 3 , R 4 and R 5 is selected from OH, C 1-6 alkoxy, C 1-6 haloalkoxy, HO-C 1-3 alkyl, NH 2 -C 1-3 alkyl, HS-C 1-3 alkyl, SH, NH 2 , C 1-6 alkylamino and di(C 1-6 alkyl)amino. <EOS>